Transmucosal delivery platform for T3s designed to enhance absorption of the T3s by facilitating sublingual and buccal absorption.
TransT3 has been shown to improve the bioavailability of T3s in a Phase Ia clinical study.
For more information on how the transmucosal delivery platform (TransT3) works, click here.
Prodrug delivery platform for T3s designed to enhance absorption of T3s into the lymphatic system of the gut and release of T3s into the blood stream.
TPDs shown in animal studies to promote the release of T3s into the bloodstream and increase bioavailability.
For more information on how the tocotrienol prodrug delivery platform (TPD) works, click here.
TransT3 and TPD platforms are non-invasive delivery methods for T3s designed to bypass digestion in the gut and metabolism in the liver (first pass metabolism) and delivering T3s into the blood stream without the use of invasive techniques such as needles and surgical implants
ABN 16 657 241 533